IL-17 Blockade in Psoriasis.

Burkett, Patrick R; Kuchroo, Vijay K

Burkett, Patrick R; Kuchroo, Vijay K.

Afiliação

Burkett PR; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham & Women's Hospital, Boston, MA 02115, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, MA 02115, USA.
Kuchroo VK; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham & Women's Hospital, Boston, MA 02115, USA. Electronic address: vkuchroo@evergrande.hms.harvard.edu.

Cell ; 167(7): 1669, 2016 Dec 15.

Article em En | MEDLINE | ID: mdl-27984714

RESUMO

IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

Assuntos

Anticorpos Monoclonais Humanizados/uso terapêutico; Anticorpos Monoclonais/uso terapêutico; Interleucina-17/antagonistas & inibidores; Psoríase/tratamento farmacológico; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Interleucina-17 / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google